Divi's Laboratories (DIVISLAB) Aktienübersicht
Divi's Laboratories Limited beschäftigt sich mit der Herstellung und dem Verkauf von generischen pharmazeutischen Wirkstoffen (APIs), Zwischenprodukten und Nutrazeutika in Indien, Nordamerika, Asien, Europa und auf internationaler Ebene. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 0/6 |
| Künftiges Wachstum | 3/6 |
| Vergangene Leistung | 4/6 |
| Finanzielle Gesundheit | 6/6 |
| Dividenden | 4/6 |
DIVISLAB Community Fair Values
Create NarrativeSee what 20 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Divi's Laboratories Limited Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | ₹8,597.00 |
| 52-Wochen-Hoch | ₹8,674.00 |
| 52-Wochen-Tief | ₹5,636.50 |
| Beta | 0.22 |
| 1 Monat Veränderung | 16.39% |
| 3 Monate Veränderung | 24.83% |
| 1 Jahr Veränderung | 39.75% |
| 3 Jahre Veränderung | 136.41% |
| 5 Jahre Veränderung | 75.07% |
| Veränderung seit IPO | 97,454.61% |
Aktuelle Nachrichten und Updates
Narrative-Update • Aug 20
DIVISLAB: Upcoming June Quarter Results Will Support Bullish Outlook
Analysts have adjusted their price target on Divi's Laboratories from about ₹8,795 to about ₹10,953, reflecting updated views on its fair value, discount rate, revenue growth and profit margin assumptions, as well as the P/E they apply to the stock. What’s in the News for Divi's Laboratories Divi's Laboratories has scheduled a Board meeting on August 1, 2026.
Narrative-Update • Aug 06
DIVISLAB: Elevated Future P/E Will Continue To Signal Overvaluation Risk
Analysts have nudged their fair value estimate for Divi's Laboratories higher from ₹5,610 to ₹6,000, citing a slightly lower discount rate, modestly adjusted revenue growth assumptions, and a small improvement in expected profit margins and future P/E levels. What's in the News for Divi's Laboratories Board meeting scheduled on May 23, 2026, to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.Analyseartikel • Aug 04
Divi's Laboratories Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
A week ago, Divi's Laboratories Limited ( NSE:DIVISLAB ) came out with a strong set of quarterly numbers that could...Narrative-Update • Jul 23
DIVISLAB: Elevated Future P/E Will Continue To Signal Overvaluation Risk
Analysts have revised their price target for Divi's Laboratories to ₹5,610 from ₹5,333.98, citing updated assumptions for revenue growth, profit margins, and future P/E that collectively support a higher fair value estimate despite a slightly higher discount rate. What’s in the News for Divi's Laboratories A board meeting is scheduled on August 1, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.Recent updates
Narrative-Update • Aug 20
DIVISLAB: Upcoming June Quarter Results Will Support Bullish Outlook
Analysts have adjusted their price target on Divi's Laboratories from about ₹8,795 to about ₹10,953, reflecting updated views on its fair value, discount rate, revenue growth and profit margin assumptions, as well as the P/E they apply to the stock. What’s in the News for Divi's Laboratories Divi's Laboratories has scheduled a Board meeting on August 1, 2026.Narrative-Update • Aug 06
DIVISLAB: Elevated Future P/E Will Continue To Signal Overvaluation Risk
Analysts have nudged their fair value estimate for Divi's Laboratories higher from ₹5,610 to ₹6,000, citing a slightly lower discount rate, modestly adjusted revenue growth assumptions, and a small improvement in expected profit margins and future P/E levels. What's in the News for Divi's Laboratories Board meeting scheduled on May 23, 2026, to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.Analyseartikel • Aug 04
Divi's Laboratories Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
A week ago, Divi's Laboratories Limited ( NSE:DIVISLAB ) came out with a strong set of quarterly numbers that could...Narrative-Update • Jul 23
DIVISLAB: Elevated Future P/E Will Continue To Signal Overvaluation Risk
Analysts have revised their price target for Divi's Laboratories to ₹5,610 from ₹5,333.98, citing updated assumptions for revenue growth, profit margins, and future P/E that collectively support a higher fair value estimate despite a slightly higher discount rate. What’s in the News for Divi's Laboratories A board meeting is scheduled on August 1, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.
Narrative-Update • Jul 08
DIVISLAB: Upcoming Board Decisions And Fair Value Assumptions Will Shape Balanced Outlook
Analysts have modestly raised their price target for Divi's Laboratories from ₹6,875 to approximately ₹7,059, citing updated assumptions around fair value, discount rate, revenue growth, profit margins and future P/E expectations. What's in the News Divi's Laboratories has scheduled a board meeting on May 23, 2026, at 10:15 Indian Standard Time to review audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.Narrative-Update • Jun 24
DIVISLAB: Upcoming Board Meeting And Dividend Decision Will Support Bullish Outlook
Analysts have adjusted their fair value estimate for Divi's Laboratories slightly lower from ₹8,812.63 to ₹8,795.18, reflecting small tweaks to assumptions on the discount rate, revenue growth, profit margin and future P/E multiples. What’s in the News for Divi's Laboratories A board meeting is scheduled for May 23, 2026, at 10:15 Indian Standard Time to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.Narrative-Update • Jun 09
DIVISLAB: Upcoming Board Meeting And Dividend Decision Will Support Bullish Outlook
Analysts have raised their fair value estimate for Divi's Laboratories from ₹8,620.23 to ₹8,812.63, reflecting updated assumptions for the discount rate, revenue growth, profit margins and future P/E expectations. What's in the News A board meeting is scheduled for May 23, 2026, at 10:15 IST to review and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.Narrative-Update • May 26
DIVISLAB: Elevated Future P/E Will Continue To Signal Overvaluation Risk
Analysts have lifted Divi's Laboratories price target from ₹5,133.17 to ₹5,333.98, citing updated assumptions on revenue growth, profit margins, and future P/E expectations. What's in the News A board meeting is scheduled for May 23, 2026, at 10:15 Indian Standard Time to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026 (Key Developments).Analyseartikel • May 26
Divi's Laboratories Limited (NSE:DIVISLAB) Just Released Its Annual Results And Analysts Are Updating Their Estimates
Divi's Laboratories Limited ( NSE:DIVISLAB ) last week reported its latest yearly results, which makes it a good time...Narrative-Update • May 04
DIVISLAB: Elevated Future P/E Will Remain A Key Overvaluation Risk
Analysts have trimmed their price target on Divi's Laboratories slightly from ₹5,140 to about ₹5,133, reflecting updated assumptions around discount rates, revenue growth, profit margin, and future P/E expectations. Valuation Changes Fair Value: Trimmed slightly from ₹5,140.00 to about ₹5,133.17 per share.Narrative-Update • Apr 20
DIVISLAB: Upcoming Board Review Will Support Bullish Long Term Outlook
Analysts have lifted their price target for Divi's Laboratories slightly, with fair value now seen around ₹8,620 versus about ₹8,554 earlier, reflecting updated assumptions for discount rate, revenue growth, profit margin and future P/E. What's in the News A board meeting is scheduled on Feb 11, 2026 to consider and approve unaudited standalone financial results for the quarter and nine months ended Dec 31, 2025 (Key Developments).Narrative-Update • Apr 05
DIVISLAB: Elevated Future P/E Will Persist Despite Unchanged Fair Value Estimate
Analysts have maintained Divi's Laboratories' fair value estimate at ₹5,140 per share, with only small tweaks to assumptions such as discount rate, revenue growth, profit margin, and future P/E, which together guide the latest price target narrative. What's in the News Board meeting scheduled for February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Narrative-Update • Mar 22
DIVISLAB: Upcoming Board Review And Fair Value Update Signal Constructive Outlook
Analysts have made a small upward adjustment to the fair value estimate for Divi's Laboratories to around ₹6,875, reflecting slightly updated assumptions on the discount rate, revenue growth, profit margins and future P/E. What's in the News Board meeting scheduled on February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).Narrative-Update • Mar 08
DIVISLAB: Rich Future P/E Will Persist Despite Softer Outlook After Results
Analysts have trimmed their price target on Divi's Laboratories from ₹5,290 to ₹5,140, reflecting updated assumptions around a slightly lower revenue growth outlook, a marginally higher profit margin, a modestly reduced future P/E multiple, and an adjusted discount rate. What's in the News A board meeting is scheduled for February 11, 2026 to review and approve unaudited standalone and consolidated financial results for the quarter ended December 31, 2025 (Key Developments).Narrative-Update • Feb 22
DIVISLAB: Upcoming Results Review Will Shape Balanced Long Term Outlook
Narrative Update on Divi's Laboratories The analyst price target for Divi's Laboratories has been adjusted slightly higher from about ₹6,823 to roughly ₹6,870, with analysts pointing to small refinements in assumptions around discount rate, revenue growth, profit margin and future P/E as the drivers of this change. What's in the News A board meeting is scheduled for February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).Narrative-Update • Feb 07
DIVISLAB: Upcoming Results Review Will Support Bullish Long Term Outlook
Analysts have lifted their price target on Divi's Laboratories slightly to ₹6,823 from about ₹6,785, citing refreshed assumptions around discount rates, revenue growth, profit margin and future P/E that remain broadly in line with prior views. What's in the News A board meeting is scheduled for February 11, 2026, to review and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Narrative-Update • Jan 24
DIVISLAB: Management Changes And Rich Future P/E Will Sustain Excessive Optimism
Analysts now cite slightly higher assumptions on growth, profitability and future P/E in their models for Divi's Laboratories, which feeds into an updated fair value estimate of ₹5,290, compared with the previous ₹5,035.89. What's in the News Board meeting scheduled for November 7, 2025, at 10:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).Narrative-Update • Jan 10
DIVISLAB: Upcoming Board Review And Management Changes Will Support Bullish Outlook
Analysts have raised their price target for Divi's Laboratories from ₹7,750 to about ₹8,554, citing updated assumptions related to revenue growth, profit margins and future P/E levels in their models. What's in the News Board meeting scheduled on Nov 07, 2025 at 10:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and half year ended Sep 30, 2025 (company filing).Analyseartikel • Dec 30
Earnings Not Telling The Story For Divi's Laboratories Limited (NSE:DIVISLAB)
Divi's Laboratories Limited's ( NSE:DIVISLAB ) price-to-earnings (or "P/E") ratio of 68.3x might make it look like a...Narrative-Update • Dec 25
DIVISLAB: Rising Profitability Expectations Will Mask Moderating Revenue And Justify Excessive Optimism
Analysts have raised their price target for Divi's Laboratories from ₹4,756 to ₹5,036, citing expectations of stronger profitability and a slightly richer future valuation multiple, despite moderating revenue growth assumptions. What's in the News Board meeting scheduled for November 7, 2025 at 10:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).Narrative-Update • Dec 11
DIVISLAB: Upcoming Board Meeting And Leadership Review Will Shape Fair Outlook
Analysts have nudged their price target for Divi's Laboratories slightly higher, reflecting marginal improvements in discount rate assumptions and long term growth expectations that together support a fair value estimate of ₹6,785.10 per share. What's in the News Board meeting scheduled for November 7, 2025, at 10:30 IST to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).Analyseartikel • Dec 09
Divi's Laboratories (NSE:DIVISLAB) Seems To Use Debt Quite Sensibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Narrative-Update • Nov 27
DIVISLAB: Upcoming Board Decisions And Modest Earnings Improvements Will Shape Outlook
Analysts have raised their fair value estimate for Divi's Laboratories from ₹6,433 to ₹6,785, citing modest improvements in revenue growth and profit margin expectations. What's in the News A board meeting is scheduled for November 7, 2025, at 10:30 IST to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (Key Developments).Analyseartikel • Nov 15
Investors Shouldn't Be Too Comfortable With Divi's Laboratories' (NSE:DIVISLAB) Earnings
Despite posting some strong earnings, the market for Divi's Laboratories Limited's ( NSE:DIVISLAB ) stock hasn't moved...Analyseartikel • Nov 11
Divi's Laboratories Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Divi's Laboratories Limited ( NSE:DIVISLAB ) just released its latest interim results and things are looking bullish...Narrative-Update • Nov 08
DIVISLAB: Upcoming Board Decisions And Modest Earnings Improvements Will Shape Outlook
Analysts have modestly increased their price target for Divi's Laboratories from ₹6,363 to ₹6,433, citing slight improvements in projected revenue growth and profit margins as the underlying factors. What's in the News Upcoming Board Meeting scheduled for November 7, 2025, at 10:30 AM IST.Analyseartikel • Sep 06
Divi's Laboratories Limited's (NSE:DIVISLAB) Share Price Could Signal Some Risk
With a price-to-earnings (or "P/E") ratio of 69.2x Divi's Laboratories Limited ( NSE:DIVISLAB ) may be sending very...Narrative-Update • Sep 05
Custom Synthesis And Capacity Expansion Will Unlock Global Demand
With both the consensus price target and future P/E ratio for Divi's Laboratories remaining virtually unchanged, analysts signal stable valuation expectations, resulting in a steady fair value assessment at ₹6363. What's in the News Board meeting scheduled to consider and approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2025.
Neues Narrative • Nov 10
Tactical Expansions And Innovation Could Offset Generic Pricing Pressures And Boost Profitability
Strategic investments in peptide synthesis and greenfield expansion enhance future revenue potential through capacity and product line growth.Aktionärsrenditen
| DIVISLAB | IN Life Sciences | IN Markt | |
|---|---|---|---|
| 7D | 1.4% | 1.0% | -0.2% |
| 1Y | 39.8% | 22.3% | 2.4% |
Rendite im Vergleich zur Industrie: DIVISLAB übertraf die Branche Indian Life Sciences , die im vergangenen Jahr eine Rendite von 22.3 erzielte.
Rendite vs. Markt: DIVISLAB übertraf den Markt Indian, der im vergangenen Jahr eine Rendite von 2.4 erzielte.
Preisvolatilität
| DIVISLAB volatility | |
|---|---|
| DIVISLAB Average Weekly Movement | 3.6% |
| Life Sciences Industry Average Movement | 5.5% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 3.6% |
Stabiler Aktienkurs: DIVISLAB hatte in den letzten 3 Monaten im Vergleich zum Indian -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: DIVISLABDie wöchentliche Volatilität (4%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1990 | 11,565 | Kiran Divi | www.divislabs.com |
Divi's Laboratories Limited beschäftigt sich mit der Herstellung und dem Verkauf von generischen pharmazeutischen Wirkstoffen (APIs), Zwischenprodukten und Nutrazeutika in Indien, Nordamerika, Asien, Europa und international. Das Unternehmen übernimmt auch die Auftragssynthese von APIs und Zwischenprodukten und liefert eine Reihe von Carotinoiden wie Betacarotin, Astaxanthin, Lycopin und Canthaxanthin sowie andere Fertigprodukte, darunter Lutein, und Vitamine an die Lebensmittel-, Nahrungsergänzungs- und Futtermittelindustrie. Das Unternehmen exportiert auch seine Produkte.
Divi's Laboratories Limited's Grundlagenzusammenfassung
| DIVISLAB grundlegende Statistiken | |
|---|---|
| Marktanteil | ₹2.28t |
| Gewinn(TTM) | ₹29.25b |
| Umsatz(TTM) | ₹112.30b |
78.0x
Kurs-Gewinn-Verhältnis 20.3x
Kurs-Umsatz-VerhältnisIst DIVISLAB zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| DIVISLAB Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | ₹112.30b |
| Kosten der Einnahmen | ₹43.53b |
| Bruttogewinn | ₹68.77b |
| Sonstige Ausgaben | ₹39.52b |
| Gewinn | ₹29.25b |
Zuletzt gemeldete Gewinne
Jun 30, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | 110.18 |
| Bruttomarge | 61.24% |
| Nettogewinnspanne | 26.05% |
| Schulden/Eigenkapital-Verhältnis | 0.04% |
Wie hat sich DIVISLAB auf lange Sicht entwickelt?
Historische Performance und VergleicheDividenden
0.3%
Aktuelle Dividendenrendite31%
AusschüttungsquoteZahlt DIVISLAB eine zuverlässige Dividende?
Siehe DIVISLAB Dividendenhistorie und Benchmarks| Divi's Laboratories Dividendentermine | |
|---|---|
| Ex-Dividenden Datum | Jul 24 2026 |
| Datum der Dividendenzahlung | Sep 09 2026 |
| Tage bis Ex-Dividende | 30 days |
| Tage bis zum Datum der Dividendenzahlung | 17 days |
Zahlt DIVISLAB eine zuverlässige Dividende?
Siehe DIVISLAB Dividendenhistorie und BenchmarksUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/21 14:37 |
| Aktienkurs zum Tagesende | 2026/08/21 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2026/03/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Divi's Laboratories Limited wird von 53 Analysten beobachtet. 29 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Pranav Chawla | Ambit Capital |
| Gaurav Tinani | Ambit Capital |